Get started
INmune Bio Inc.INmune Bio Inc.INmune Bio Inc.

INmune Bio Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

INMB chart


Full chart

INMB upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪169.84 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.18 USD
Net income (FY)
‪−30.01 M‬ USD
Revenue (FY)
‪155.00 K‬ USD
Shares float
‪15.76 M‬
Beta (1Y)
1.80

Employees


Employees (FY)
17
Change (1Y)
+7 +70.00%
Revenue / Employee (1Y)
‪9.12 K‬ USD
Net income / Employee (1Y)
‪−1.77 M‬ USD

About INmune Bio Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Raymond J. Tesi
Website
inmunebio.com
Headquarters
Boca Raton
Founded
2015
FIGI
BBG00LW94L98
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

INMB news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of INMB is 7.80 USD — it has decreased by −4.25% in the past 24 hours. Watch INmune Bio Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange INmune Bio Inc. stocks are traded under the ticker INMB.
INMB stock has fallen by −17.19% compared to the previous week, the month change is a −2.79% fall, over the last year INmune Bio Inc. has showed a −40.37% decrease.
We've gathered analysts' opinions on INmune Bio Inc. future price: according to them, INMB price has a max estimate of 30.00 USD and a min estimate of 20.00 USD. Watch INMB chart and read a more detailed INmune Bio Inc. stock forecast: see what analysts think of INmune Bio Inc. and suggest that you do with its stocks.
INMB reached its all-time high on Sep 7, 2021 with the price of 30.37 USD, and its all-time low was 2.20 USD and was reached on Mar 16, 2020. View more price dynamics on INMB chart.
See other stocks reaching their highest and lowest prices.
INMB stock is 5.48% volatile and has beta coefficient of 1.80. Track INmune Bio Inc. stock price on the chart and check out the list of the most volatile stocks — is INmune Bio Inc. there?
Today INmune Bio Inc. has the market capitalization of ‪169.84 M‬, it has decreased by −21.28% over the last week.
Yes, you can track INmune Bio Inc. financials in yearly and quarterly reports right on TradingView.
INmune Bio Inc. is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
INMB earnings for the last quarter are −0.60 USD per share, whereas the estimation was −0.51 USD resulting in a −18.42% surprise. The estimated earnings for the next quarter are −0.55 USD per share. See more details about INmune Bio Inc. earnings.
INmune Bio Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of 333.00 USD. In the next quarter, revenue is expected to reach 0.00 USD.
INMB net income for the last quarter is ‪−12.09 M‬ USD, while the quarter before that showed ‪−9.75 M‬ USD of net income which accounts for −24.08% change. Track more INmune Bio Inc. financial stats to get the full picture.
No, INMB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 27, 2025, the company has 17.00 employees. See our rating of the largest employees — is INmune Bio Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INmune Bio Inc. EBITDA is ‪−41.55 M‬ USD, and current EBITDA margin is ‪−19.19 K‬%. See more stats in INmune Bio Inc. financial statements.
Like other stocks, INMB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INmune Bio Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So INmune Bio Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating INmune Bio Inc. stock shows the sell signal. See more of INmune Bio Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.